Avenzo Therapeutics

Avenzo Therapeutics, based in San Diego, in-licenses Chinese oncology assets for Western development, including the Nectin-4 by TROP2 bispecific antibody-drug conjugate AVZO-103 and a CDK2 inhibitor. Its pipeline comprises AVZO-103, AVZO-021, the CDK2 inhibitor, and AVZO-1418, an EGFR by HER3 ADC. OnCo links it to Nectin-4 and TROP2 as targets and to the bispecific ADC technology. Whether a company that licenses rather than discovers can differentiate in a crowded bispecific ADC field is the open question. The bispecific ADC page carries the wider context.